首页> 外文期刊>International angiology: A journal of the International Union of Angiology >Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.
【24h】

Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.

机译:肝素酶I抗性糖胺聚糖在受污染肝素中的分子谱分析。与未污染的肝素和猪过硫酸化硫酸软骨素的比较研究。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

AIM: Heparin is a widely used anticoagulant which is usually obtained from porcine mucosal tissue. The structure of heparin is comparable to other naturally occurring glycosaminoglycans such as chondroitin sulfate and dermatan sulfate. The commercially available heparin preparations may contain small amounts of dermatan sulfate as a carry-over impurity. More recently (November 2007 to April 2008), an increased incidence of adverse events and deaths associated with the use of heparin alerted regulatory agencies to investigate the composition of heparin. As a result, oversulfated chondroitin sulfate was found to be the main determinant of the observed adverse reactions. This glycosaminoglycan is not usually found in the mammalian tissues. METHODS: This investigation reports on the comparison of contaminant free and contaminated heparins and their digestion by heparinase-I. It also describes the molecular profile of the contaminant isolated from the recalled heparin preparations in comparison to oversulfated chondroitin sulfate. The anticoagulant and anti-Xa activities are also reported. RESULTS: The contaminant is found to be comparable to the synthesized OSCS as both were resistant to heparinase-I digestion. The contaminant and OSCS exhibited weaker anticoagulant activities than heparin and did not have any anti-Xa effects. CONCLUSION: This data strongly suggests that such glycosaminoglycans as chondroitin sulfate can be structurally modified to exhibit anticoagulant activities and their molecular weight can be adjusted to mimic heparin.
机译:目的:肝素是一种广泛使用的抗凝剂,通常从猪粘膜组织获得。肝素的结构与其他天然存在的糖胺聚糖如硫酸软骨素和硫酸皮肤素相当。市售肝素制剂可包含少量硫酸皮肤素作为残留杂质。最近(2007年11月至2008年4月),与使用肝素相关的不良事件和死亡的发生率增加,提醒监管机构调查肝素的成分。结果,发现过硫酸化软骨素是观察到的不良反应的主要决定因素。这种糖胺聚糖通常不在哺乳动物组织中发现。方法:本研究报告比较了无污染物和受污染的肝素及其通过肝素酶Ⅰ的消化。还描述了与回收的硫酸软骨素硫酸盐相比,从回收的肝素制剂中分离出的污染物的分子特征。还报道了抗凝血和抗Xa活性。结果:发现该污染物与合成的OSCS相当,因为两者均对肝素酶I消化具有抵抗力。污染物和OSCS的抗凝活性比肝素弱,并且没有任何抗Xa的作用。结论:该数据强烈表明,可将诸如硫酸软骨素的糖胺聚糖进行结构修饰以表现出抗凝活性,并可以调节其分子量以模仿肝素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号